CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of multiple myeloma (MM), Waldenström macroglobulinemia (WM) and amyloidosis (AL).
  
  OVERVIEW OF ACTIVITY
  Hematologic cancers include the lymphomas, the leukemias, multiple myeloma and other related disorders stemming from lymphoid and myeloid progenitor cell lines. Taken together, it is estimated that approximately 174,250 new lymphoid, myeloid and leukemic cancer cases will be identified in the United States in the year 2018, and 56,100 individuals will die from these diseases. Importantly, nearly 70 drug products are currently labeled for use in the management of hematologic cancers with more than 120 distinct FDA-approved indications. Although this extensive list of available treatment options is reassuring for patients and oncology healthcare professionals, it poses a challenge to the practicing clinician who must maintain up-to-date knowledge of their appropriate application across a vast spectrum of tumor types. This is particularly true within the realm of myeloma, where the past several years have yielded a staggering number of important clinical and research advances.
  
  These proceedings from a CME symposium during the ASH Annual Meeting use the perspectives of a group of community oncologists gathered during a daylong working group to establish and subsequently address some of the most frequently encountered questions and controversies facing clinicians involved in the management of this disease. By providing information on the latest research developments and their potential application to routine practice, this activity is designed to assist hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of MM, WM and AL with the formulation of up-to-date clinical management strategies.
  
  LEARNING OBJECTIVES

  • Customize the use of induction, consolidation and maintenance therapeutic approaches for patients with MM in the transplant and nontransplant settings, considering patient- and disease-related factors, including cytogenetic profile.
  • Consider published research data and other clinical factors in the best-practice selection, sequencing or combining of available therapies in the nonresearch care of patients with relapsed/refractory (R/R) MM.
  • Appreciate the mechanisms of action of, supportive research database with and FDA-endorsed indications for monoclonal antibodies directed at CD38 and SLAMF7, and effectively identify where and how these agents should be integrated into the clinical management of R/R MM.
  • Design and implement a plan of care to recognize and manage side effects and toxicities associated with the use of existing and recently approved systemic therapies to support quality of life and continuation of treatment.
  • Develop an evidence-based algorithm for the use of stem cell transplant, chemotherapy and/or novel targeted agents for the management of primary AL.
  • Consider clinical and other patient-related factors in the sequence and selection of systemic therapy for patients with WM requiring active treatment.
  • Assess the ongoing clinical trials evaluating novel investigational approaches for MM, WM and AL, and obtain consent from appropriate patients for study participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  Meletios A Dimopoulos, MD
  Chairman, Department of Medical Therapeutics
  University of Athens School of Medicine
  Athens, Greece
  
  Advisory Committee: Amgen Inc, Celgene Corporation, Janssen Biotech Inc, Novartis, Onyx Pharmaceuticals, an Amgen subsidiary, Takeda Oncology.
  
  Sagar Lonial, MD
  Professor and Executive Vice Chair
  Department of Hematology and Medical Oncology
  Chief Medical Officer
  Winship Cancer Institute
  Emory University
  Atlanta, Georgia
  
  Advisory Committee: Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline, Janssen Biotech Inc, Merck, Novartis, Onyx Pharmaceuticals, an Amgen subsidiary, Takeda Oncology; Consulting Agreements: Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline, Janssen Biotech Inc, Merck, Onyx Pharmaceuticals, an Amgen subsidiary, Takeda Oncology.
  
  Nikhil C Munshi, MD
  Professor of Medicine, Harvard Medical School
  Director of Basic and Correlative Science
  Associate Director, Jerome Lipper Multiple Myeloma Center
  Department of Medical Oncology
  Dana-Farber Cancer Institute
  Boston, Massachusetts
  
  Consulting Agreements: Celgene Corporation, Janssen Biotech Inc, Merck, OncoPep, Pfizer Inc, Takeda Oncology; Ownership Interest: OncoPep.
  
  Robert Z Orlowski, MD, PhD
  Florence Maude Thomas Cancer Research Professor
  Chair Ad Interim, Department of Lymphoma and Myeloma
  Professor, Department of Experimental Therapeutics
  Division of Cancer Medicine
  The University of Texas MD Anderson Cancer Center
  Houston, Texas
  
  Advisory Committee and Consulting Agreements: Bristol-Myers Squibb Company, Celgene Corporation, Takeda Oncology; Contracted Research: Bristol-Myers Squibb Company, Celgene Corporation, Forma Therapeutics, Karus Therapeutics, Onyx Pharmaceuticals, an Amgen subsidiary, Spectrum Pharmaceuticals Inc, Takeda Oncology.
  
  Noopur Raje, MD
  Director, Center for Multiple Myeloma
  Massachusetts General Hospital Cancer Center
  Professor of Medicine
  Harvard Medical School
  Boston, Massachusetts
  
  Consulting Agreements: Amgen Inc, Celgene Corporation, Onyx Pharmaceuticals, an Amgen subsidiary, Takeda Oncology; Contracted Research: Acetylon Pharmaceuticals Inc, Lilly.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.
  
  RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AbbVie Inc, Adaptive Biotechnologies, AstraZeneca Pharmaceuticals LP/Acerta Pharma, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Genentech BioOncology, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Pharmacyclics LLC, an AbbVie Company, Seattle Genetics and Takeda Oncology.
  
  Hardware/Software Requirements:
  A high-speed Internet connection
  A monitor set to 1280 x 1024 pixels or more
  Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
  Adobe Flash Player 27 plug-in or later
  Adobe Acrobat Reader
  (Optional) Sound card and speakers for audio
  
  Last review date: March 2018
  Expiration date: March 2019